Can AMH levels predict the need for increased medication during IVF/ICSI in PCOS women?

Kamel, Ahmed; Ramadan, Wafaa; Dahab, Sherif; Elsherbini, Moutaz; Lasheen, Yossra; Abuhamila, Fouad A.

doi:10.1080/14767058.2016.1272567

Cited by 11 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are consistent with previous researches done by Amer et al in 2013[21] and by Ahmed Kamel et al in 2017 [14]. Both of them showed that PCOS with markedly raised circulating AMH were resistant to HMG stimulation and might require a higher starting dose.…”

Section: Discussionsupporting

confidence: 93%

Can AMH levels predict the need to step up FSH dose for controlled ovarian stimulation in PCOS women?

Huang

Gao

Shi

et al. 2023

Preprint

View full text Add to dashboard Cite

Background To explore the role of anti-Mullerian hormone (AMH) in predicting the need to step up recombinant FSH (rFSH) dose in IVF/ICSI cycles of polycystic ovarian syndrome (PCOS) women. Methods This is a retrospective cohort study of 825 PCOS related infertility enrolled from Jan 2019 to Dec 2021. The daily rFSH dose at which the first response to rFSH were recorded. The dose at which the first response to rFSH was based on folliculometry during follow up in which two or more follicles reached ≥ 11mm. A receiver operating characteristic (ROC) curve analysis was done to investigate the ability of AMH to predict the need to step up initial rFSH dose. Results PCOS women who needed to step up initial rFSH dose had a significantly higher AMH compared with those didn’t step up initial rFSH dose (11.37 ± 3.25ng/ml vs. 8.69 ± 3.16ng/ml, P < 0.001). In multivariate logistic regression analysis, increased AMH level was an independent factor for the need to step up initial rFSH dose in PCOS patients after adjusted for confounding factors. ROC curve analysis showed AMH could predict the need to step up initial rFSH dose (AUC = 0.738, 95%CI: 0.704–0.773), having 75.4% specificity and 63% sensitivity when the threshold AMH concentration was 9.30ng/ml. 58.8% PCOS women with AMH > 9.30 ng/ml required increased rFSH dose compared to 18.8% of women with AMH ≤ 9.30ng/ml (p < 0.001). Although the clinical pregnancy rate and live birth rate were not significantly different, there was a higher incidence of OHSS among women with AMH > 9.30 ng/ml vs. AMH ≤ 9.30ng/ml (20.8% vs. 15.3%, p = 0.043). Conclusion PCOS women with AMH > 9.30 ng/ml were resistant to rFSH stimulation and require increased dose for the cycle recruitment of ovarian follicles.

show abstract

Section: Discussionsupporting

confidence: 93%

Can AMH levels predict the need to step up FSH dose for controlled ovarian stimulation in PCOS women?

Huang

Gao

Shi

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Another study showed that PCOS patients with higher serum AMH levels have a lower possibility of response to clomiphene or LET [ 23 ]. Besides, high serum AMH levels are associated with a significantly lower probability of response to human menopausal gonadotrophin stimulation [ 24 , 25 ]. High AMH is associated with lower live birth rates in women with PCOS undergoing assisted reproductive technology [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Predictors of response to ovulation induction using letrozole in women with polycystic ovary syndrome

Guo

Chen

et al. 2023

BMC Endocr Disord

View full text Add to dashboard Cite

Background This study aimed to evaluate the predictive value of the initial screening characteristics of women with anovulatory polycystic ovary syndrome (PCOS) who did or did not respond to 2.5 mg letrozole (LET). Methods The clinical and laboratory characteristics of women with PCOS who underwent LET treatment were evaluated. Women with PCOS were stratified according to their responses to LET (2.5 mg). The potential predictors of their responses to LET were estimated using logistic regression analysis. Results Our retrospective study included 214 eligible patients with a response to 2.5 mg LET (n = 131) or no response to 2.5 mg LET (n = 83). PCOS patients who responded to 2.5 mg LET showed better outcomes than those who did not (2.5 mg LET) for pregnancy rate, live birth rate, pregnancy rate per patient, and live birth rate per patient. Logistic regression analyses showed that late menarche (odds ratio [OR], 1.79 [95% confidence intervals (CI), 1.22–2.64], P = 0.003), and increased anti-müllerian hormone (AMH) (OR, 1.12 [95% CI, 1.02–1.23], P = 0.02), baseline luteinizing hormone (LH)/ follicle stimulating hormone (FSH) (OR, 3.73 [95% CI, 2.12–6.64], P < 0.001), and free androgen index (FAI) (OR, 1.37 [95% CI, 1.16–1.64], P < 0.001) were associated with a higher possibility of no response to 2.5 mg LET. Conclusions PCOS patients with an increased LH/FSH ratio, AMH, FAI, and late menarche may need an increased dosage of LET for a treatment response, which could be helpful in designing a personalized treatment strategy.

show abstract

“… 22 They were associated with gonadotrophin dosages and risks of severe OHSS in PCOS patients undergone IVF. 23 So people proposed AMH as one of the factors related to the degree of severity of PCOS. 24 Follicular fluid is the site for oocyte growth and development.…”

Section: Discussionmentioning

confidence: 99%

Chinese herbal medicine (Bu-Shen-Tian-Jing Formula) for outcomes of IVF in Chinese patients with polycystic ovary syndrome: A retrospective cohort study

Pan

Zhang

et al. 2022

Integrative Medicine Research

View full text Add to dashboard Cite

Background Polycystic ovary syndrome (PCOS) is one of the most common causes of anovulatory infertility. Chinese herbal medicine (CHM) has many advantages in treating PCOS. We conducted a retrospective cohort study to investigate the effects of CHM (Bu-Shen-Tian-Jing Formula, BSTJF) on the outcomes of IVF in Chinese patients with PCOS and the potential underlying mechanism. Methods A total of 111 patients with PCOS who undergone IVF between November 2009 and July 2018 were included. Fifty-four patients received a three-month BSTJF therapy before controlled ovarian hyperstimulation, while the other 57 patients didn't. The data of the PCOS patients was collected. Anti-Müllerian hormone (AMH), growth differentiation factor-8 (GDF-8) levels in the follicular fluid were evaluated. Results BSTJF helped patients with PCOS to get more retrieved oocytes (P<0.05) and fertilized oocytes (P<0.05). The clinical cumulative pregnancy rate, live birth rate, and term delivery rate were significantly higher in the same stimulated cycle of the PCOS patients with BSTJF treatment (P<0.05). No significant differences existed between the two groups in the rate of fertilization, hospitalization rate of ovarian hyper stimulation syndrome and obstetrical or neonatal complications. BSTJF significantly decreased the AMH levels in the follicular fluids (P<0.05). Conclusion BSTJF significantly may improve the outcomes of IVF in Chinese patients with PCOS through decreasing AMH levels in follicular fluids. However, the evidence is limited due to the small sample size and the several potential bias.

show abstract

Can AMH levels predict the need for increased medication during IVF/ICSI in PCOS women?

Abstract: PCOS with AMH >4.6 ng/ml are resistant to HMG stimulation, require dose step up during ART cycles, and are at higher risk for severe OHSS.

Cited by 11 publications

References 18 publications

Can AMH levels predict the need to step up FSH dose for controlled ovarian stimulation in PCOS women?

Can AMH levels predict the need to step up FSH dose for controlled ovarian stimulation in PCOS women?

Predictors of response to ovulation induction using letrozole in women with polycystic ovary syndrome

Chinese herbal medicine (Bu-Shen-Tian-Jing Formula) for outcomes of IVF in Chinese patients with polycystic ovary syndrome: A retrospective cohort study

Contact Info

Product

Resources

About